Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882791 · ClinicalTrials.gov registry record
Basal Cell Carcinoma Recurrence After Mohs Surgery
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 115
- Enrollment target
NCT00882791 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 115 participants.
The verdict
NCT00882791 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement. Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882791
The ClinicalTrials.gov registry entry for NCT00882791 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00882791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882791 about?
NCT00882791 is a clinical study titled "Basal Cell Carcinoma Recurrence After Mohs Surgery". Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surger...
What is the current status of trial NCT00882791?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2008-05. Estimated completion is 2009-05.
Who is sponsoring clinical trial NCT00882791?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.